Login
Enter your Progress In Mind Portugal username.
Enter the password that accompanies your username.

Request new password

Home

Progress in Mind Portugal

  • Topics
    • Depression
    • Migraine
    • Schizophrenia
  • Congress highlights
    • EAN 2022
    • AAN 2022
    • AHS 2022
    • AAN 2021
    • AHS 2021
    • IHC 2021
    • SIRS 2019
    • EPA 2019
    • EPA 2018
    • APA 2018
    • ECNP 2017
  • About
  • Podcasts
  • Newsletter signup

Search

Main navigation

  • Home
  • Lundbeck Therapeutic Area Australia
  • Progress in Mind Korea Focus Area
  • Progress in Mind Spain Focus Area
  • 전문가 칼럼
  • 찾아보기

Tools

  • 찾아보기
  • User Profile

User account menu

  • Log in
  • Reset your password
Powered by Drupal

The information on this site is exclusively intented for health care professionals.

Accept Decline
Schizophrenia 12 Aug, 2019

Video #6: Which patients are best suited for long-acting injectable antipsychotics?

 Professor John Kane discusses the often-asked question, who is the ideal candidate for long-acting antipsychotic treatment?

Sign up for Progress in Mind Portugal newsletter

Sign up for our newsletter and stay updated on new content and resources.

Related

Depression
Congress highlights

Psychotic depression – From biology to the clinic

Migraine
Congress highlights Article

Raising the healthcare prioritization of headache: Why and how?

Alzheimer's Disease
Congress highlights

Latest insights into CADASIL and disorders of consciousness

Social Networks

Progress in Mind Portugal HCP Access verification required

To gain access, please provide details to verify you are a healthcare professional.

If you are not located in Portugal click here.

Continue to verification page Login with email

Brought to you by

 Lundbeck

© 2021

PROGRESS IN MIND PORTUGAL

Cookies

Condições de Utilização

subscribe newsletter

Sign up for newsletter

Register as a health care professional

Login as a registered health care professional

Please enter your email to continue

By submitting this form you agree that your email is sent to a third party for validation.

Read the full terms and conditions here.